Lineage Cell Therapeutics (LCTX) Other Working Capital Changes (2018 - 2023)

Lineage Cell Therapeutics' Other Working Capital Changes history runs 12 years deep, the most recent figure standing at -$3.0 million for Q2 2023.

• In Q2 2023, Other Working Capital Changes rose 28.53% year-over-year to -$3.0 million; the TTM figure through Jun 2023 stood at -$9.4 million (down 4.22% YoY), while the FY2022 annual figure was -$13.4 million, down 3614.21% from the prior year.
• Other Working Capital Changes for Q2 2023 stood at -$3.0 million, down from -$2.1 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $6.5 million in Q4 2023, with the low at -$12.8 million in Q4 2022.
• The 5-year median for Other Working Capital Changes is -$598000.0 (2024), against an average of -$850941.2.
• The sharpest annual moves came in 2021 and 2022: Other Working Capital Changes jumped 537.93% in 2021, then sank 5556.98% in 2022.
• Lineage Cell Therapeutics' Other Working Capital Changes stood at -$378000.0 in 2019, then soared by 69.31% to -$116000.0 in 2020, then sank by 248.28% to -$404000.0 in 2021, then plunged by 336.39% to -$1.8 million in 2022, then tumbled by 67.84% to -$3.0 million in 2023.
• Business Quant data shows LCTX's Other Working Capital Changes at -$3.0 million in Q2 2023, -$2.1 million in Q1 2023, and -$1.8 million in Q4 2022.